Galectin Therapeutics Inc financial data

Symbol
GALT on Nasdaq
Industry
Pharmaceutical Preparations
Location
4960 Peachtree Industrial Boulevard, Suite 240, Norcross, Georgia
State of incorporation
Nevada
Fiscal year end
December 31
Former names
PRO PHARMACEUTICALS INC (to 5/26/2011)
Latest financial report
Q1 2024 - May 15, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 193 % +4.79%
Debt-to-equity -137 % +17.2%
Return On Equity 68.3 % -49.5%
Return On Assets -170 % +10%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 61.9 M shares +4.14%
Common Stock, Shares, Outstanding 62.1 M shares +4.31%
Entity Public Float 63 M USD +6.78%
Common Stock, Value, Issued 61 K USD +3.39%
Weighted Average Number of Shares Outstanding, Basic 62 M shares +4.2%
Weighted Average Number of Shares Outstanding, Diluted 62 M shares +4.2%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 31.4 M USD -3.37%
General and Administrative Expense 5.99 M USD -4.59%
Operating Income (Loss) -37.4 M USD +3.56%
Nonoperating Income (Expense) -3.65 M USD -126%
Net Income (Loss) Attributable to Parent -41 M USD -1.63%
Earnings Per Share, Basic -0.74 USD/shares -10.4%
Earnings Per Share, Diluted -0.74 USD/shares -10.4%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 23.6 M USD +32.3%
Assets, Current 25.5 M USD +30.2%
Property, Plant and Equipment, Net 0 USD
Operating Lease, Right-of-Use Asset 45 K USD -42.3%
Other Assets, Noncurrent 430 K USD -36.1%
Assets 25.9 M USD +28%
Accounts Payable, Current 3.8 M USD +48.7%
Employee-related Liabilities, Current 518 K USD +34.2%
Accrued Liabilities, Current 8.84 M USD -1.6%
Liabilities, Current 12.6 M USD +9.54%
Operating Lease, Liability, Noncurrent 7 K USD -87.3%
Other Liabilities, Noncurrent 7 K USD -87.3%
Liabilities 97 M USD +54.2%
Retained Earnings (Accumulated Deficit) -366 M USD -13.9%
Stockholders' Equity Attributable to Parent -72.8 M USD -64.1%
Liabilities and Equity 25.9 M USD +28%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -12.1 M USD -12.2%
Net Cash Provided by (Used in) Financing Activities 10 M USD 0%
Net Cash Provided by (Used in) Investing Activities 0 USD
Common Stock, Shares Authorized 150 M shares 0%
Common Stock, Shares, Issued 62.1 M shares +4.31%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 23.6 M USD +30.9%
Deferred Tax Assets, Valuation Allowance 78.4 M USD +19.1%
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent 0.21 pure 0%
Deferred Tax Assets, Gross 78.4 M USD +19.1%
Operating Lease, Liability 55 K USD -43.3%
Lessee, Operating Lease, Liability, to be Paid 57 K USD -46.7%
Property, Plant and Equipment, Gross 74 K USD 0%
Operating Lease, Liability, Current 48 K USD +14.3%
Lessee, Operating Lease, Liability, to be Paid, Year Two 18 K USD -64.7%
Lessee, Operating Lease, Liability, to be Paid, Year One 18 K USD -64.7%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 2 K USD -80%
Lessee, Operating Lease, Liability, to be Paid, Year Three 18 K USD
Deferred Tax Assets, Operating Loss Carryforwards 61.4 M USD +15.6%
Preferred Stock, Shares Issued 1.24 M shares -1.98%
Preferred Stock, Shares Authorized 1.74 M shares 0%
Additional Paid in Capital 292 M USD +5.92%
Preferred Stock, Shares Outstanding 1.24 M shares -1.98%
Deferred Tax Assets, Net of Valuation Allowance 0 USD
Share-based Payment Arrangement, Expense 2.2 M USD -17.5%
Interest Expense 3.38 M USD +167%